Show simple item record

Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies

dc.contributor.authorBirdwell, Kelly A.
dc.contributor.authorRangaswami, Janani
dc.contributor.authorMathew, Roy O.
dc.contributor.authorParasuraman, Raviprasenna
dc.contributor.authorTantisattamo, Ekamol
dc.date.accessioned2020-03-25T21:59:33Z
dc.date.available2020-03-25T21:59:33Z
dc.date.issued2019-05
dc.identifier.citationJanani Rangaswami, Roy O Mathew, Raviprasenna Parasuraman, Ekamol Tantisattamo, Michelle Lubetzky, Swati Rao, Muhammad S Yaqub, Kelly A Birdwell, William Bennett, Pranav Dalal, Rajan Kapoor, Edgar V Lerma, Mark Lerman, Nicole McCormick, Sripal Bangalore, Peter A McCullough, Darshana M Dadhania, on behalf of the American Society of Transplantation’s Kidney-Pancreas Community of Practice (AST-KPCOP) Cardiovascular Disease Workgroup, Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies, Nephrology Dialysis Transplantation, Volume 34, Issue 5, May 2019, Pages 760–773, https://doi.org/10.1093/ndt/gfz053en_US
dc.identifier.issn0931-0509
dc.identifier.urihttps://ir.vanderbilt.edu/xmlui/handle/1803/9869
dc.descriptionOnly Vanderbilt University affiliated authors are listed on VUIR. For a full list of authors, access the version of record at https://www.researchgate.net/publication/333393303_Cardiovascular_disease_in_the_kidney_transplant_recipient_epidemiology_diagnosis_and_management_strategiesen_US
dc.description.abstractKidney transplantation (KT) is the optimal therapy for end-stage kidney disease (ESKD), resulting in significant improvement in survival as well as quality of life when compared with maintenance dialysis. The burden of cardiovascular disease (CVD) in ESKD is reduced after KT; however, it still remains the leading cause of premature patient and allograft loss, as well as a source of significant morbidity and healthcare costs. All major phenotypes of CVD including coronary artery disease, heart failure, valvular heart disease, arrhythmias and pulmonary hypertension are represented in the KT recipient population. Pre-existing risk factors for CVD in the KT recipient are amplified by superimposed cardio-metabolic derangements after transplantation such as the metabolic effects of immunosuppressive regimens, obesity, posttransplant diabetes, hypertension, dyslipidemia and allograft dysfunction. This review summarizes the major risk factors for CVD in KT recipients and describes the individual phenotypes of overt CVD in this population. It highlights gaps in the existing literature to emphasize the need for future studies in those areas and optimize cardiovascular outcomes after KT. Finally, it outlines the need for a joint 'cardio-nephrology' clinical care model to ensure continuity, multidisciplinary collaboration and implementation of best clinical practices toward reducing CVD after KT.en_US
dc.language.isoen_USen_US
dc.publisherNEPHROLOGY DIALYSIS TRANSPLANTATIONen_US
dc.subjectcardiovascular diseaseen_US
dc.subjectchronic kidney diseaseen_US
dc.subjectkidney transplantationen_US
dc.subjectmultidisciplinary managementen_US
dc.subjectrisk factorsen_US
dc.subjectCONGESTIVE-HEART-FAILUREen_US
dc.subjectSTAGE RENAL-DISEASEen_US
dc.subjectPOSTTRANSPLANT DIABETES-MELLITUSen_US
dc.subjectVASCULAR OUTCOME REDUCTIONen_US
dc.subjectCORONARY-ARTERY-DISEASEen_US
dc.subjectBLOOD-PRESSURE CONTROLen_US
dc.subjectPOST HOC ANALYSISen_US
dc.subjectPULMONARY-HYPERTENSIONen_US
dc.subjectPATIENT SURVIVALen_US
dc.subjectRISK-FACTORSen_US
dc.titleCardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategiesen_US
dc.typeArticleen_US


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record